Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06604442 · ClinicalTrials.gov registry record · Phase 4
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
A Phase 4 study of Prostate Cancer, sponsored by Blue Earth Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
- 9
- Study locations
NCT06604442: Completed Phase 4 study of Prostate Cancer, sponsored by Blue Earth Diagnostics.
NCT06604442 is a Phase 4 study of Prostate Cancer that has completed, run by Blue Earth Diagnostics. The registered enrollment target is 55 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06604442, a Phase 4 study of Prostate Cancer, has completed, sponsored by Blue Earth Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
- 9
- Study locations
Study Summary
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Primary Outcome
Difference in urinary bladder mean SUV (SUVmean) between piflufolastat (18F) and flotufolastat (18F). A positive difference represents a lower bladder SUVmean for flotufolastat (18F) compared to piflufolastat (18F).
Conditions Studied
Interventions
- DRUG Flotufolastat (18F)
- DRUG piflufolastat (18F)
Study Locations (9)
California
- City of Hope Medical Center - Duarte
- Tower Urology - Los Angeles
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic - Jacksonville
Illinois
- Endeavor Health- Glenbrook Hospital - Glenview
Nebraska
- XCancer Omaha/Urology Cancer Center - Omaha
New York
- Montefiore Medical Center - The Bronx
Ohio
- Cleveland Clinic - Cleveland
Texas
- Urology San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2025-08-29 |
| Phase | Phase 4 |
What the finished NCT06604442 record still lists
NCT06604442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Flotufolastat (18F) is the first listed.
NCT06604442 lists 9 locations in 8 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT06604442 about?
NCT06604442 is a clinical study titled "Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy". Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
What is the current status of trial NCT06604442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2024-12-04. Estimated completion is 2025-08-29.
What conditions does trial NCT06604442 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06604442?
The interventions under investigation include: Flotufolastat (18F) (DRUG), piflufolastat (18F) (DRUG).
Who is sponsoring clinical trial NCT06604442?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06604442 being conducted?
This trial has 9 study locations across Arizona, California, Florida, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06604442's enrollment target sits among peer trials
55 456th of 735 higher than 277 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RECRUITING · Phase 4
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RECRUITING · Phase 4
-
Gadopiclenol in Contrast Enhanced MRI of the Prostate
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI